tiprankstipranks
Immunovant (IMVT)
NASDAQ:IMVT

Immunovant (IMVT) Stock Forecast & Price Target

666 Followers
See the Price Targets and Ratings of:

IMVT Analyst Ratings

Strong Buy
11Ratings
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Immunovant
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IMVT Stock 12 Months Forecast

Average Price Target

$51.55
▲(46.03% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $51.55 with a high forecast of $57.00 and a low forecast of $48.00. The average price target represents a 46.03% change from the last price of $35.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","58":"$58","24.25":"$24.3","35.5":"$35.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$57.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.55,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$51.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,24.25,35.5,46.75,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Mar<br/>2024","25":"Mar<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.3,36.96923076923077,38.638461538461534,40.30769230769231,41.97692307692307,43.646153846153844,45.315384615384616,46.98461538461538,48.65384615384615,50.323076923076925,51.99230769230769,53.66153846153846,55.330769230769235,{"y":57,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.3,36.55,37.8,39.05,40.3,41.55,42.8,44.05,45.3,46.55,47.8,49.05,50.3,{"y":51.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.3,36.276923076923076,37.253846153846155,38.230769230769226,39.207692307692305,40.184615384615384,41.16153846153846,42.138461538461534,43.11538461538461,44.09230769230769,45.06923076923077,46.04615384615384,47.02307692307692,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.02,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.2,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.66,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.55,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.9,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.99,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.23,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.55,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.78,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.93,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$57.00Average Price Target$51.55Lowest Price Target$48.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank
$50.00
Buy
41.64%
Upside
Initiated
12/11/23
Immunovant initiated with bullish view at Deutsche Bank, here's whyImmunovant initiated with bullish view at Deutsche Bank, here's why
UBS
$56.00
Buy
58.64%
Upside
Reiterated
12/01/23
Immunovant (IMVT) PT Raised to $56 at UBSUBS analyst Colin Bristow raised the price target on Immunovant (NASDAQ: IMVT) to $56.00 (from $55.00) while maintaining a Buy rating.
Truist Financial
$48.00
Buy
35.98%
Upside
Reiterated
11/15/23
Immunovant (IMVT) PT Raised to $48 at Truist SecuritiesTruist Securities analyst Robyn Karnauskas raised the price target on Immunovant (NASDAQ: IMVT) to $48.00 (from $30.00) while maintaining a Buy rating.
Cantor Fitzgerald
$45.00
Buy
27.48%
Upside
Reiterated
10/16/23
Immunovant price target raised to $45 from $30 at Cantor FitzgeraldImmunovant price target raised to $45 from $30 at Cantor Fitzgerald
Guggenheim
$48.00
Buy
35.98%
Upside
Reiterated
09/27/23
Immunovant price target raised to $48 from $32 at GuggenheimImmunovant price target raised to $48 from $32 at Guggenheim

Best Analysts Covering Immunovant

Which Analyst Should I Follow If I Want to Buy IMVT and Sell After:
1 Month
Sam SlutskyLifeSci Capital
Success Rate
17/24 ratings generated profit
71%
Average Return
+7.80%
reiterated a buy rating 20 days ago
Copying Sam Slutsky's trades and holding each position for 1 Month would result in 70.83% of your transactions generating a profit, with an average return of +7.80% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Sam SlutskyLifeSci Capital
Success Rate
14/24 ratings generated profit
58%
Average Return
+13.93%
reiterated a buy rating 20 days ago
Copying Sam Slutsky's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +13.93% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Thomas SmithLeerink Partners
Success Rate
12/20 ratings generated profit
60%
Average Return
+70.86%
reiterated a buy rating 20 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +70.86% per trade.
2 Years
Douglas TsaoH.C. Wainwright
Success Rate
15/21 ratings generated profit
71%
Average Return
+138.70%
reiterated a buy rating 19 days ago
Copying Douglas Tsao's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +138.70% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IMVT Analyst Recommendation Trends

Rating
Sep 23
Oct 23
Nov 23
Dec 23
Feb 24
Strong Buy
5
4
7
7
5
Buy
18
18
22
22
28
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
22
29
29
33
In the current month, IMVT has received 33 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IMVT average Analyst price target in the past 3 months is $51.55.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

IMVT Financial Forecast

IMVT Earnings Forecast

Next quarter’s earnings estimate for IMVT is -$0.43 with a range of -$0.49 to -$0.37. The previous quarter’s EPS was -$0.29. IMVT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.92% of the time in the same period. In the last calendar year IMVT has Underperformed its overall industry.
Next quarter’s earnings estimate for IMVT is -$0.43 with a range of -$0.49 to -$0.37. The previous quarter’s EPS was -$0.29. IMVT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.92% of the time in the same period. In the last calendar year IMVT has Underperformed its overall industry.
No data currently available

IMVT Sales Forecast

Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.89% of the time in the same period. In the last calendar year IMVT has Underperformed its overall industry.
Next quarter’s sales forecast for IMVT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. IMVT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.89% of the time in the same period. In the last calendar year IMVT has Underperformed its overall industry.

IMVT Stock Forecast FAQ

What is IMVT’s average 12-month price target, according to analysts?
Based on analyst ratings, Immunovant’s 12-month average price target is $51.55.
    What is IMVT’s upside potential, based on the analysts’ average price target?
    Immunovant has 46.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IMVT a Buy, Sell or Hold?
          Immunovant has a conensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Immunovant’s price target?
            The average price target for Immunovant is $51.55. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $57.00 ,the lowest forecast is $48.00. The average price target represents 46.03% Increase from the current price of $35.3.
              What do analysts say about Immunovant?
              Immunovant’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of IMVT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis